We are live on ! Find out more
SC

Stempoint Capital Portfolio holdings

AUM $522M
1-Year Est. Return 281.95%
This Fund
S&P 500
This Quarter Est. Return
-9.68%
1 Year Est. Return
+281.95%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$340M
AUM Growth
-$38.1M
Cap. Flow
+$16M
Cap. Flow %
4.71%
Top 10 Hldgs %
55.38%
Holding
79
New
17
Increased
14
Reduced
10
Closed
36

Top Buys

Rank Stock Value
1
IMCR icon
Immunocore
IMCR
+$17.3M
2
IMVT icon
Immunovant
IMVT
+$10.9M
3
MRK icon
Merck
MRK
+$10.5M
4
GSK icon
GSK
GSK
+$10.3M
5
ACLX
Arcellx
ACLX
+$7.63M

Top Sells

Rank Stock Value
1
LLY icon
Eli Lilly
LLY
+$11.7M
2
ARQT icon
Arcutis Biotherapeutics
ARQT
+$11.2M
3
ROIV icon
Roivant Sciences
ROIV
+$9.22M
4
TARS icon
Tarsus Pharmaceuticals
TARS
+$8.08M
5
INSM icon
Insmed
INSM
+$7.19M

Sector Composition

Rank Sector Weight
1 Healthcare 99.45%
2 Financials 0.44%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
FULC icon
26
Fulcrum Therapeutics
FULC
$233M
$4.32M 1.27%
696,464
+289,356
+71% +$2.19M
NRIX icon
27
Nurix Therapeutics
NRIX
$2.39B
$4.24M 1.25%
+203,273
New +$3.17M
PYXS icon
28
Pyxis Oncology
PYXS
$141M
$3.98M 1.17%
1,202,675
-591,520
-33% -$2.49M
JANX icon
29
Janux Therapeutics
JANX
$966M
$3.89M 1.14%
92,949
-28,693
-24% -$1.35M
IDYA icon
30
IDEAYA Biosciences
IDYA
$3.46B
$3.57M 1.05%
101,787
+14,394
+16% +$570K
SYRE icon
31
Spyre Therapeutics
SYRE
$8.17B
$3.54M 1.04%
150,450
+88,197
+142% +$2.97M
CATX icon
32
Perspective Therapeutics
CATX
$336M
$3.43M 1.01%
+343,810
New +$4.97M
JSPR icon
33
Jasper Therapeutics
JSPR
$21.7M
$3.26M 0.96%
143,775
+14,564
+11% +$349K
BDTX icon
34
Black Diamond Therapeutics
BDTX
$104M
$3.14M 0.92%
+674,198
New +$3.62M
VIGL
35
DELISTED
Vigil Neuroscience
VIGL
$2.98M 0.88%
+744,412
New +$2.55M
NGNE icon
36
Neurogene
NGNE
$728M
$2.86M 0.84%
+78,601
New +$2.77M
SLN
37
Silence Therapeutics
SLN
$516M
$2.37M 0.7%
+124,866
New +$2.66M
TARA icon
38
Protara Therapeutics
TARA
$229M
$2.05M 0.6%
984,113
+815,671
+484% +$2.38M
BBOT
39
BridgeBio Oncology
BBOT
$666M
$2.04M 0.6%
200,000
– –
SRZN icon
40
Surrozen
SRZN
$241M
$1.57M 0.46%
+143,510
New +$1.48M
PCSC
41
Perceptive Capital Solutions
PCSC
$124M
$1.51M 0.44%
+150,000
New +$1.51M
PRAX icon
42
Praxis Precision Medicines
PRAX
$8.59B
$1.21M 0.36%
29,259
+2,366
+9% +$112K
ARQT icon
43
CALL
Arcutis Biotherapeutics
ARQT
$3.47B
$350K 0.1%
+500,000
New +$4.52M
ACLX
44
PUT
DELISTED
Arcellx
ACLX
– –
-50,000
Closed -$135K
ANAB icon
45
AnaptysBio
ANAB
$1.6B
– –
-269,548
Closed -$6.07M
ANNX icon
46
Annexon
ANNX
$965M
– –
-605,117
Closed -$4.34M
ARQT icon
47
PUT
Arcutis Biotherapeutics
ARQT
$3.47B
– –
-825,000
Closed -$516K
ATXS
48
DELISTED
Astria Therapeutics
ATXS
– –
-230,273
Closed -$2.68M
AUTL
49
CALL
Autolus Therapeutics
AUTL
$389M
– –
-250,000
Closed -$68.8K
AVDL
50
DELISTED
Avadel Pharmaceuticals
AVDL
– –
-223,660
Closed -$3.78M
1
2
3 4

Similar funds

JE
JMAC Enterprises Newtown, Pennsylvania $522M AUM 15.34% 1-Year Est. Return
GS
GWN Securities Palm Beach Gardens, Florida $523M AUM 20.1% 1-Year Est. Return
LT
Legacy Trust Grand Rapids, Michigan $522M AUM 23.56% 1-Year Est. Return
WFA
WestHill Financial Advisors San Rafael, California $523M AUM 15.95% 1-Year Est. Return
TCM
TruNorth Capital Management Kalamazoo, Michigan $522M AUM 14.26% 1-Year Est. Return
SCM
Shah Capital Management Raleigh, North Carolina $521M AUM 46.95% 1-Year Est. Return
ETS
ESL Trust Services Rochester, New York $524M AUM 17.18% 1-Year Est. Return
CM
Conifer Management New York $524M AUM 14.11% 1-Year Est. Return

Stempoint Capital's Q2 2024 Portfolio in Review

As of Q2 2024, Stempoint Capital held 79 positions worth $340M, down 10% from $378M the previous quarter. Its ten largest holdings account for 55% of the portfolio.

Stempoint Capital deployed $16M of net new capital in Q2 2024, opening 17 new positions and adding to 14 existing holdings. Its largest new stake was Immunocore: 339,351 shares worth $11.5M.

By sector, the portfolio is most concentrated in Healthcare at 99% of assets, up from 99% a quarter earlier, followed by Financials.

On the sell side, the largest reduction was Arcutis Biotherapeutics, an estimated $11.2M trimmed.

  • Stempoint Capital's largest Q2 2024 buy was Immunocore: 339,351 shares worth $11.5M.
  • Stempoint Capital added most to Immunovant in Q2 2024, an estimated $10.9M increase.
  • Stempoint Capital's biggest Q2 2024 reduction was Arcutis Biotherapeutics, cutting an estimated $11.2M.
  • Stempoint Capital fully exited Eli Lilly in Q2 2024, selling an estimated $11.7M.
  • Stempoint Capital's ten largest holdings make up 55% of its $340M portfolio in Q2 2024.
  • Stempoint Capital opened 17 new positions and closed 36 in Q2 2024.
  • Stempoint Capital's portfolio value fell 10% quarter-over-quarter to $340M.

Based on Stempoint Capital's 13F filing for Q2 2024, filed 13 Aug 2024.